Table 1.
Molecular characteristics of GES-positive isolates and transconjugantsa
| Strainb | Isolation date (mo/day/yr) | Hospitalc | Ward | Origin | Plasmid size(s) (kb) | Incompatibility group | PMQR gene | ESBL gene type(s) |
MIC (mg/ml) |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-GES | GES | CAZ | CAZ/CLA | CTX | PIP | PIP/TAZ | CPO | IMP | IMP/CLA | MER | Gm | ||||||||
| K01201 | 11/27/2006 | 1 | Hematology | Blood | 220, 140, 90, 40 | NA | qnrA1/qnrS1/aac (6′)-Ib-cr | SHV-11 | 19, 20 | 256 | 128 | >256 | 128 | 128 | >32 | 1 | 0.25 | 0.125 | 8 |
| TK01201 | Not applicable | Not applicable | Not applicable | Not applicable | 40 | FIIs | qnrA1/aac(6′)-Ib-cr | Neg | 19, 20 | 256 | 4 | 64 | 64 | 16 | <0.002 | 1 | 0.25 | 0.125 | 2 |
| K01239 | 10/10/2008 | 1 | ICU | Wound | 190, 160, 40 | NA | Neg | SHV-11 | 19, 20 | >256 | >256 | 128 | 128 | 128 | >32 | 32 | 16 | 8 | 16 |
| TK01239 | Not applicable | Not applicable | Not applicable | Not applicable | 40 | FIIs | Neg | Neg | 19, 20 | 256 | 4 | 64 | 256 | 16 | <0.002 | 0.5 | 0.125 | 0.03 | 2 |
| K01256 | 09/22/2006 | 1 | OR | Wound | 190, 120, 110, 40 | NA | Neg | SHV-26 | 19, 20 | >256 | >256 | 256 | 512 | 512 | 32 | 16 | 16 | 32 | 4 |
| TK01256 | Not applicable | Not applicable | Not applicable | Not applicable | 40 | FIIs | Neg | SHV-26 | 19, 20 | >256 | 16 | 64 | 128 | 16 | <0.002 | 0.5 | 0.125 | 0.03 | 2 |
| K01295 | 04/01/2009 | 1 | OR | Catheter | 200, 100, 40 | NA | qnrA1 | SHV-1 | 19, 20 | 256 | 8 | 32 | 128 | 256 | >32 | 1 | 0.25 | 0.125 | 8 |
| TK01295 | Not applicable | Not applicable | Not applicable | Not applicable | 40 | FIIs | qnrA1 | Neg | 19, 20 | 256 | 8 | 64 | 256 | 128 | <0.002 | 0.5 | 0.125 | 0.03 | 2 |
| K06220 | 09/14/10 | 2 | ICU | Urine | 180, 100, 50, 40 | NA | qnrS1/aac(6′)-Ib-cr | SHV-5 | 19, 20 | 64 | 16 | 64 | 512 | 256 | >32 | 1 | 0.5 | 0.5 | >64 |
| TK06220 | Not applicable | Not applicable | Not applicable | Not applicable | 50, 40 | FIIsd | aac(6′)-Ib-cr | SHV-5 | 19, 20 | 64 | 4 | 32 | 128 | 8 | <0.002 | 1 | 0.25 | 0.03 | 2 |
| E01298 | 06/20/2009 | 1 | Nephrology | Urine | 110, 40 | NA | aac(6′)-Ib-cr | CTX-M-15 | 19, 20 | >256 | 8 | >256 | >512 | 64 | >32 | 0.5 | 0.25 | 0.5 | 4 |
| TE01298 | Not applicable | Not applicable | Not applicable | Not applicable | 40 | FIIs | aac(6′)-Ib-cr | CTXM-15 | 19, 20 | 256 | 8 | 64 | 64 | 4 | <0.002 | 0.5 | 0.125 | 0.03 | 2 |
| E09280 | 03/10/2009 | 3 | Hematology | Blood | 190, 40 | NA | aac(6′)-Ib-cr | Neg | 19, 20 | >256 | 16 | 128 | 32 | 8 | >32 | 1 | 0.125 | 0.125 | 2 |
| TE09280 | Not applicable | Not applicable | Not applicable | Not applicable | 40 | FIIs | aac(6′)-Ib-cr | Neg | 19, 20 | 256 | 8 | 64 | 32 | 8 | <0.002 | 1 | 0.125 | 0.125 | 2 |
| Kx09201 | 09/26/2007 | 3 | Hematology | Blood | 220, 190, 100, 80 | NA | qnrB2 | SHV-12/CTX-M-15 | 1 | 64 | 0.5 | >256 | >512 | 8 | 32 | 0.25 | 0.0625 | 0.015 | 64 |
| TKx09201 | Not applicable | Not applicable | Not applicable | Not applicable | 80 | FIIs | qnrB2 | SHV-12/CTXM-15 | 1 | 32 | 1 | >256 | >512 | 8 | <0.002 | 0.25 | 0.0625 | 0.015 | 32 |
| E. coli J53-2 | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | NA | Not applicable | Not applicable | Not applicable | 0.5 | 0.25 | 0.0625 | 8 | 8 | <0.002 | 0.125 | 0.0625 | 0.015 | 0.5 |
a
CAZ, ceftazidime; CLA, clavulanic acid; CTX, cefotaxime; PIP, piperacillin; TAZ, tazobactam; CPO, ciprofloxacin; IMP, imipenem; MER, meropenem; Gm, gentamicin; ICU, intensive care ward; NA, not analyzed; Neg, negative; OR, operating room.
b
K, K. pneumoniae; E, E. coli; Kx, K. oxytoca; T, transconjugant.
c
Hospitals: 1, Hospital Civil de Guadalajara (HCG); 2, Hospital Universitario (CRCEI); 3, Instituto Nacional de Cancerología (INCan).
d
Additional incompatibility group identified in transconjugants FIIy, FIIk, and IncR (see text).